Nordexia PeptideResearch peptide catalogCustom peptide synthesis · technical documentation
Contact the technical team
Practical articles organized by catalog use, documentation review, custom planning, and research procurement.
Choose a category to narrow the published guidance.
13 articles
The research status of TB-500 can be summarized as: animal data support, missing human data, evidence transfer controversy, and new metabolite findings. This article reviews the current evidence landscape and future directions.
Read guidance →
The most important lesson from the Paradigm case is not that "one vendor got caught." It is that the risk in this market was never only the molecule. This article explains where the risks are, and how buyers can protect themselves.
Read guidance →
The regulatory history of CJC-1295 and Ipamorelin spans the 2023 Category 2 classification, the 2024 lawsuit and two unanimous votes, and the 2026 thaw they were skipped by. This article presents the full record as a timeline.
Read guidance →
GLOW is a convenient three-peptide combination, but it locks the only factor you can control — each peptide’s dose — to the supplier’s chosen ratio. This article offers an honest assessment framework.
Read guidance →
Cagrilintide was developed by Novo Nordisk under the code AM833, with a half-life extended to 159–195 hours, enabling once-weekly dosing. The CagriSema NDA was submitted to the FDA on 18 December 2025, with a decision expected in 2026. This article lays out the key milestones and unpublished results in chronological order.
Read guidance →
This article answers the 10 most common questions about retatrutide in a Q&A format, covering mechanism, weight-loss data, dosing, side effects, liver injury, legality, WADA status, and approval timeline.
Read guidance →
In July 2026, the FDA Pharmacy Compounding Advisory Committee will hold a hearing on BPC-157 and other Category 2 peptides. This article explains what is actually happening, what it means for compounded peptides, and what regulatory steps remain.
Read guidance →
The 10 most frequently asked questions about BPC-157 and the gut barrier: tight junction proteins, Zonulin, leaky gut, NF-κB, macrophages, gut microbiome, and oral absorption. This article answers them all.
Read guidance →
The 10 most frequently asked questions about peptides: how to test receptor binding, what structure-activity relationships are, why some peptides trigger immune responses, how peptides cross the blood-brain barrier, and whether they can be personalized. This article answers them all.
Read guidance →
A practical checklist for identifying a catalog record and giving the review team enough information to answer accurately.
Read guidance →
Understand the difference between a catalog statement, a mapped historical file, and documentation for the material currently being quoted.
Read guidance →
The sequence, modification, purity, quantity, analytical, destination, and timing details that make a custom request reviewable.
Read guidance →
A controlled way to compare identity, specification, evidence, destination requirements, and lead time before a purchase decision.
Read guidance →